Novel approaches for targeting kinases: Allosteric inhibition, allosteric activation and pseudokinases

Future Medicinal Chemistry

Volumn 6, Issue 5, 2014, Pages 541-561

  Cowan Jacob, Sandra W ^a   Jahnke, Wolfgang ^a   Knapp, Stefan ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ALLOSTERISM; DRUG INDUSTRY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; NEOPLASM; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; BINDING SITES; DATABASES, PROTEIN; HUMANS; MOLECULAR DOCKING SIMULATION; PHARMACOKINETICS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE;

EID: 84896920166     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.216     Document Type: Review

References (174)

1. Blue Ridge institute for medical research in horse shoe. www.brimr.org/PKI/PKIs.htm
2. Sartore-Bianchi A, Ricotta R, Cerea G, Maugeri MR, Siena S. Rationale and clinical results of multi-target treatments in oncology. Int. J. Biol. Markers 22(1 Suppl. 4), S77-S87 (2007).
3. Rauch J, Volinsky N, Romano D, Kolch W. The secret life of kinases: functions beyond catalysis. Cell Commun. Signal. 9(1), 23 (2011).
4. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 298(5600), 1912-1934 (2002).
5. The human kinome online. http://kinase.com/kinbase
6. Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62(15), 4236-4243 (2002).
7. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2), 129-141 (2005).
8. Manley PW, Cowan-Jacob SW, Buchdunger E et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 38(Suppl. 5), S19-S27 (2002).
9. Davis MI, Hunt JP, Herrgard S et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29(11), 1046-1051 (2011).
10. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov. 5(10), 835-844 (2006).
11. Taipale M, Krykbaeva I, Whitesell L et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol. 31, 630-637 (2013).
12. Tao ZF, Wang L, Stewart KD et al. Structurebased design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J. Med. Chem. 50(7), 1514-1527 (2007).
13. Liu Q, Sabnis Y, Zhao Z et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20(2), 146-159 (2013).
14. Meggers E, Atilla-Gokcumen GE, Bregman H et al. Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. SYNLETT 8, 1177-1189 (2007).
15. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the gatekeeper door: exploiting the active kinase conformation. J. Med. Chem. 53(7), 2681-2694 (2010).
16. Hill ZB, Perera BG, Andrews SS, Maly DJ. Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. ACS Chem. Biol. 7(3), 487-495 (2012).
17. Tomita N, Hayashi Y, Suzuki S et al. Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg. Med. Chem. Lett. 23(6), 1779-1785 (2013).
18. Heinrich T, Graedler U, Boettcher H, Blaukat A, Shutes A. Allosteric IGF-1R inhibitors. ACS Med. Chem. Lett. 1, 199-203 (2010).
19. Getlik M, Simard JR, Termathe M et al. Fluorophore labeled kinase detects ligands that bind within the MAPK insert of p38alpha kinase. PLoS ONE 7(7), e39713 (2012).
20. Uitdehaag JC, Verkaar F, Alwan H, De Man J, Buijsman RC, Zaman GJ. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 166(3), 858-876 (2012).
21. Fang ZZ, Grutter C, Rauh D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem. Biol. 8(1), 58-70 (2013).
22. Adrian FJ, Ding Q, Sim T et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2(2), 95-102 (2006).
23. Zhang J, Adrian FJ, Jahnke W et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463(7280), 501-506 (2010).
24. Iwatani M, Iwata H, Okabe A et al. Discovery and characterization of novel allosteric FAK inhibitors. Eur. J. Med. Chem. 61, 49-60 (2013).
25. Vanderpool D, Johnson TO, Ping C et al. Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 48(41), 9823-9830 (2009).
26. Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol. Cancer Ther. 8(9), 2559-2565 (2009).
27. Deacon SW, Beeser A, Fukui JA et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol. 15(4), 322-331 (2008).
28. Lindsley CW, Zhao Z, Leister WH et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15(3), 761-764 (2005).
29. Lindvall M, Karpov A, Bellamacina C et al. Discovery of novel and highly selective allosteric inhibitors of PAK1. Presented at: 246th ACS National Meeting and Exposition. IN, USA, 8-12 September 2013.
30. Iwata H, Oki H, Okada K et al. A back-tofront fragment-based drug design search strategy targeting the DFG-out pocket of protein tyrosine kinases. ACS Med. Chem. Lett. 3, 342-346 (2012).
31. Pargellis C, Tong L, Churchill L et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9(4), 268-272 (2002).
32. Ohren JF, Chen H, Pavlovsky A et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11(12), 1192-1197 (2004).
33. Simard JR, Kluter S, Grutter C et al. A new screening assay for allosteric inhibitors of cSrc. Nat. Chem. Biol. 5(6), 394-396 (2009).
34. Schneider R, Becker C, Simard JR et al. Direct binding assay for the detection of type IV allosteric inhibitors of Abl. J. Am. Chem. Soc. 134(22), 9138-9141 (2012).
35. Betzi S, Alam R, Martin M et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 6(5), 492-501 (2011).
36. Martin MP, Alam R, Betzi S, Ingles DJ, Zhu JY, Schonbrunn E. A novel approach to the discovery of small-molecule ligands of CDK2. ChemBioChem 13(14), 2128-2136 (2012).
37. Jahnke W, Grotzfeld RM, Pelle X et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J. Am. Chem. Soc. 132(20), 7043-7048 (2010).
38. Hardy JA, Wells JA. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 14(6), 706-715 (2004).
39. Erlanson DA, Ballinger MD, Wells JA. Tethering. Methods Princ. Med. Chem. 34 , 285-310 (2006).
40. Dennis MS, Eigenbrot C, Skelton NJ et al. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 404, 465-470 (2000).
41. Navratilova I, Macdonald G, Robinson C et al. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action. J. Biomol. Screen. 17(2), 183-193 (2012).
42. Comess KM, Sun C, Abad-Zapatero C et al. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem. Biol. 6(3), 234-244 (2011).
43. Ashwell MA, Lapierre JM, Brassard C et al. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl) pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J. Med. Chem. 55(11), 5291-5310 (2012).
44. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64(18), 6652-6659 (2004).
45. Stockman BJ, Kothe M, Kohls D et al. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem. Biol. Drug Design 73(2), 179-188 (2009).
46. Kumar A, Voet A, Zhang KYJ. Fragment based drug design: from experimental to computational approaches. Curr. Med. Chem. 19, 5128-5147 (2012).
47. Jahnke W, Perez LB, Paris CG, Strauss A, Fendrich G, Nalin CM. Second-site NMRr screening with a spin-labeled first ligand. J. Am. Chem. Soc. 122, 7394-7395 (2000).
48. Jahnke W, Blommers MJJ, Fernandez C, Zwingelstein C, Amstutz R. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors. ChemBioChem 6, 1607-1610 (2005).
49. McCoy MA, Senior MM, Wyss DF. Screening of protein kinases by ATP-STD NMR spectroscopy. J. Am. Chem. Soc. 127(22), 7978-7979 (2005).
50. Vazquez J, De SK, Chen L-H et al. Development of paramagnetic probes for molecular recognition studies in protein kinases. J. Med. Chem. 51, 3460-3465 (2008).
51. Moy FJ, Lee A, Gavrin LK et al. Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance. J. Med. Chem. 53, 1238-1249 (2010).
52. Stebbins JL, De SK, Machleidt T et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl Acad. Sci. USA. 105, 16809-16813 (2008).
53. Engel M, Hindie V, Lopez-Garcia LA et al. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J. 25(23), 5469-5480 (2006).
54. Wei L, Gao X, Warne R et al. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Bioorg. Med. Chem. Lett. 20(13), 3897-3902 (2010).
55. Wilhelm A, Lopez-Garcia LA, Busschots K et al. 2-(3-oxo-1,3- diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept. J. Med. Chem. 55, 9817-9830 (2012).
56. Frohner W, Lopez-Garcia LA, Neimanis S et al. 4-benzimidazolyl-3- phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCzeta. J. Med. Chem. 54(19), 6714-6723 (2011).
57. Lopez-Garcia LA, Schulze JO, Frohner W et al. Allosteric regulation of protein kinase PKCzeta by the N-terminal C1 domain and small compounds to the PIF-pocket. Chem. Biol. 18(11), 1463-1473 (2011).
58. Nagar B, Hantschel O, Young MA et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112(6), 859-871 (2003).
59. Cowan-Jacob SW, Fendrich G, Manley PW et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13(6), 861-871 (2005).
60. Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, Shaw DE. How does a drug molecule find its target binding site? J. Am. Chem. Soc. 133(24), 9181-9183 (2011).
61. Palomo V, Soteras I, Perez DI et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J. Med. Chem. 54(24), 8461-8470 (2011).
62. Huang Z, Mou L, Shen Q et al. ASD v2.0: updated content and novel features focusing on allosteric regulation. Nucleic acids Res. 42(1), D510-D516 (2013).
63. Huang W, Lu S, Huang Z et al. Allosite: a method for predicting allosteric sites. Bioinformatics 29(18), 2357-2359 (2013).
64. Panjkovich A, Daura X. Exploiting protein flexibility to predict the location of allosteric sites. BMC Bioinform. 13, 273 (2012).
65. Li Y, Liang J, Siu T et al. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4] triazolo[3,4-f ][1,6]naphthyridines with potent and balanced activity. Bioorg. Med. Chem. Lett. 19(3), 834-836 (2009).
66. Zhao Z, Robinson RG, Barnett SF et al. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg. Med. Chem. Lett. 18(1), 49-53 (2008).
67. Converso A, Hartingh T, Garbaccio RM et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett. 19(4), 1240-1244 (2009).
68. Chen F, Hancock CN, Macias AT et al. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg. Med. Chem. Lett. 16(24), 6281-6287 (2006).
69. Hatzivassiliou G, Haling JR, Chen H et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAFdriven cancers. Nature 501(7466), 232-236 (2013).
70. Yap TA, Yan L, Patnaik A et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29 , 4688-4695 (2011).
71. Perry JJ, Harris RM, Moiani D, Olson AJ, Tainer JA. p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. J. Mol. Biol. 391(1), 1-11 (2009).
72. Rusconi P, Caiola E, Broggini M. RAS/RAF/ MEK inhibitors in oncology. Curr. Med. Chem. 19(8), 1164-1176 (2012).
73. Simpson GL, Hughes JA, Washio Y, Bertrand SM. Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery. Curr. Opin. Drug Discov. Devel. 12(5), 585-596 (2009).
74. Eglen R, Reisine T. Drug discovery and the human kinome: recent trends. Pharmacol. Ther. 130(2), 144-156 (2011).
75. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs 19(11), 1355-1366 (2010).
76. Yang J, Campobasso N, Biju MP et al. Discovery and characterization of a cellpermeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Biol. 18(2), 177-186 (2011).
77. Raina D, Pandey P, Ahmad R et al. c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage. J. Biol. Chem. 280(12), 11147-11151 (2005).
78. Caracciolo D, Valtieri M, Venturelli D, Peschle C, Gewirtz AM, Calabretta B. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science 245(4922), 1107-1110 (1989).
79. Rosti V, Bergamaschi G, Lucotti C et al. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood 86(9), 3387-3393 (1995).
80. Allington TM, Galliher-Beckley AJ, Schiemann WP. Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J. 23(12), 4231-4243 (2009).
81. Hindie V, Stroba A, Zhang H et al. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat. Chem. Biol. 5(10), 758-764 (2009).
82. Busschots K, Lopez-Garcia LA, Lammi C et al. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem. Biol. 19(9), 1152-1163 (2012).
83. Bobkova EV, Weber MJ, Xu Z et al. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J. Biol. Chem. 285(24), 18838-18846 (2010).
84. Li S, Covino ND, Stein EG, Till JH, Hubbard SR. Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor. J. Biol. Chem. 278(28), 26007-26014 (2003).
85. Liu K, Xu L, Szalkowski D et al. Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. J. Med. Chem. 43(19), 3487-3494 (2000).
86. Lee KH, Hsu EC, Guh JH et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) Activator. J. Biol. Chem. 286(45), 39247-39258 (2011).
87. Salt IP, Palmer TM. Exploiting the antiinflammatory effects of AMP-activated protein kinase activation. Expert Opin. Investig. Drugs 21(8), 1155-1167 (2012).
88. Giordanetto F, Karis D. Direct AMPactivated protein kinase activators: a review of evidence from the patent literature. Expert Opin. Ther. Pat. 22(12), 1467-1477 (2012).
89. Lipinski CA, Stam JG, Pereira JN, Ackerman NR, Hess HJ. Bronchodilator and antiulcer phenoxypyrimidinones. J. Med. Chem. 23(9), 1026-1031 (1980).
90. Saporito MS, Ochman AR, Lipinski CA, Handler JA, Reaume AG. MLR-1023 is a potent and selective allosteric activator of LYN kinase in vitro that improves glucose tolerance in vivo. J. Pharmacol. Exp. Ther. 342(1), 15-22 (2012).
91. Muller G, Wied S, Frick W. Cross talk of pp125(FAK) and pp59(LYN) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes. Mol. Cell. Biol. 20(13), 4708-4723 (2000).
92. Massa SM, Yang T, Xie Y et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest. 120(5), 1774-1785 (2010).
93. Fedorov O, Muller S, Knapp S. The (un) targeted cancer kinome. Nat. Chem. Biol. 6(3), 166-169 (2010).
94. Fedorov O, Huber K, Eisenreich A et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem. Biol. 18(1), 67-76 (2011).
95. Debdab M, Carreaux F, Renault S et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B. modulation of alternative pre-RNA splicing. J. Med. Chem. 54(12), 4172-4186 (2011).
96. Gammons MV, Fedorov O, Ivison D et al. Topical Antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol. Vis. Sci. 54(9), 6052-6062 (2013).
97. Rosenthal AS, Tanega C, Shen M et al. An inhibitor of the Cdc2-like kinase 4 (Clk4). In: Probe Reports from the NIH Molecular Libraries Program. MD, USA (2010).
98. Dudkiewicz M, Szczepinska T, Grynberg M, Pawlowski K. A novel protein kinase-like domain in a selenoprotein, widespread in the tree of life. PLoS ONE 7(2), e32138 (2012).
99. Koike T, Izumikawa T, Tamura J, Kitagawa H. FAM20B is a kinase that phosphorylates xylose in the glycosaminoglycan-protein linkage region. Biochem. J. 421(2), 157-162 (2009).
100. Ishikawa HO, Takeuchi H, Haltiwanger RS, Irvine KD. Four-jointed is a Golgi kinase that phosphorylates a subset of cadherin domains. Science 321(5887), 401-404 (2008).
101. Ishikawa HO, Xu A, Ogura E, Manning G, Irvine KD. The Raine syndrome protein FAM20C is a Golgi kinase that phosphorylates bio-mineralization proteins. PLoS ONE 7(8), e42988 (2012).
102. Tagliabracci VS, Engel JL, Wen J et al. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science 336(6085), 1150-1153 (2012).
103. Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19(8), 754-759 (2012).
104. Mukherjee K, Sharma M, Urlaub H et al. CASK Functions as a Mg2+-independent neurexin kinase. Cell 133(2), 328-339 (2008).
105. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17(1), 128-138 (2009).
106. Barr AJ, Ugochukwu E, Lee WH et al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136(2), 352-363 (2009).
107. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell. Biol. 16(9), 443-452 (2006).
108. Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb MH. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J. Biol. Chem. 275(22), 16795-16801 (2000).
109. Min X, Lee BH, Cobb MH, Goldsmith EJ. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 12(7), 1303-1311 (2004).
110. Yagi YI, Abe K, Ikebukuro K, Sode K. Kinetic mechanism and inhibitor characterization of WNK1 kinase. Biochemistry 48(43), 10255-10266 (2009).
111. Abe Y, Matsumoto S, Wei S et al. Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J. Biol. Chem. 276(47), 44003-44011 (2001).
112. Adams JA, Taylor SS. Divalent metal ions influence catalysis and active-site accessibility in the cAMP-dependent protein kinase. Protein Sci. 2(12), 2177-2186 (1993).
113. Waas WF, Dalby KN. Physiological concentrations of divalent magnesium ion activate the serine/threonine specific protein kinase ERK2. Biochemistry 42(10), 2960-2970 (2003).
114. Saitsu H, Kato M, Osaka H et al. CASK aberrations in male patients with Ohtahara syndrome and cerebellar hypoplasia. Epilepsia 53(8), 1441-1449 (2012).
115. Takanashi J, Okamoto N, Yamamoto Y et al. Clinical and radiological features of Japanese patients with a severe phenotype due to CASK mutations. Am. J. Med. Genet. A 158A(12), 3112-3118 (2012).
116. Moog U, Kutsche K, Kortum F et al. Phenotypic spectrum associated with CASK loss-of-function mutations. J. Med. Genet. 48(11), 741-751 (2011).
117. Tarpey PS, Smith R, Pleasance E et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat. Genet. 41(5), 535-543 (2009).
118. Piluso G, Damico F, Saccone V et al. A missense mutation in CASK causes FG syndrome in an Italian family. Am. J. Hum. Genet. 84(2), 162-177 (2009).
119. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl Acad. Sci. USA 106(51), 21608-21613 (2009).
120. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl Acad. Sci. USA 107(17), 7692-7697 (2010).
121. Jaiswal BS, Kljavin NM, Stawiski EW et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23(5), 603-617 (2013).
122. Zeqiraj E, Van Aalten DM. Pseudokinasesremnants of evolution or key allosteric regulators? Curr. Opin. Struct. Biol. 20(6), 772-781 (2010).
123. Qin J, Wu C. ILK: a pseudokinase in the center stage of cell-matrix adhesion and signaling. Curr. Opin. Cell. Biol. 24(5), 607-613 (2012).
124. Akhtar N, Streuli CH. An integrin-ILKmicrotubule network orients cell polarity and lumen formation in glandular epithelium. Nat. Cell. Biol. 15(1), 17-27 (2013).
125. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase-essential roles in physiology and cancer biology. J. Cell. Sci. 121(Pt 19), 3121-3132 (2008).
126. Xing Y, Qi J, Deng S, Wang C, Zhang L, Chen J. Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-tomesenchymal transition. Exp. Cell. Res. 319(13), 2058-2072 (2013).
127. Li R, Liu B, Yin H, Sun W, Yin J, Su Q. Overexpression of integrin-linked kinase (ILK) is associated with tumor progression and an unfavorable prognosis in patients with colorectal cancer. J. Mol. Histol. 44(2), 183-189 (2013).
128. Li J, Yang ZL, Ren X et al. ILK and PRDX1 are prognostic markers in squamous cell/ adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol. 34(1), 359-368 (2013).
129. Choi YP, Kim BG, Gao MQ, Kang S, Cho NH. Targeting ILK and beta4 integrin abrogates the invasive potential of ovarian cancer. Biochem. Biophys. Res. Commun. 427(3), 642-648 (2012).
130. Fukuda K, Gupta S, Chen K, Wu C, Qin J. The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. Mol. Cell. 36(5), 819-830 (2009).
131. Ekambaram R, Enkvist E, Vaasa A et al. Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1. ChemMedChem 8(6), 909-913 (2013).
132. Lavogina D, Enkvist E, Uri A. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem 5(1), 23-34 (2010).
133. Rorth P, Szabo K, Texido G. The level of C/ EBP protein is critical for cell migration during Drosophila oogenesis and is tightly controlled by regulated degradation. Mol. Cell. 6(1), 23-30 (2000).
134. Yoshida A, Kato JY, Nakamae I, Yoneda-Kato N. COP1 targets C/EBPalpha for degradation and induces acute myeloid leukemia via Trib1. Blood 122(10), 1750-1760 (2013).
135. Liang KL, Rishi L, Keeshan K. Tribbles in acute leukemia. Blood 121(21), 4265-4270 (2013).
136. Satoh T, Kidoya H, Naito H et al. Critical role of Trib1 in differentiation of tissueresident M2-like macrophages. Nature 495(7442), 524-528 (2013).
137. Mancini E, Sanjuan-Pla A, Luciani L et al. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J. 31(2), 351-365 (2012).
138. Dedhia PH, Keeshan K, Uljon S et al. Differential ability of Tribbles family members to promote degradation of C/ EBPalpha and induce acute myelogenous leukemia. Blood 116(8), 1321-1328 (2010).
139. Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T. Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood 116(15), 2768-2775 (2010).
140. Yokoyama T, Toki T, Aoki Y et al. Identification of TRIB1 R107L gain-offunction mutation in human acute megakaryocytic leukemia. Blood 119(11), 2608-2611 (2012).
141. Bowers AJ, Scully S, Boylan JF. SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia. Oncogene 22(18), 2823-2835 (2003).
142. Keeshan K, Bailis W, Dedhia PH et al. Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood 116(23), 4948-4957 (2010).
143. Toms AV, Deshpande A, McNally R et al. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 20(10), 1221-1223 (2013).
144. Silvennoinen O, Ungureanu D, Niranjan Y, Hammaren H, Bandaranayake R, Hubbard SR. New insights into the structure and function of the pseudokinase domain in JAK2. Biochem. Soc. Trans. 41(4), 1002-1007 (2013).
145. Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS ONE 5(6), e11157 (2010).
146. Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. Too many roads not taken. Nature 470(7333), 163-165 (2011).
147. Gill AL, Frederickson M, Cleasby A et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48(2), 414-426 (2005).
148. Moffett K, Konteatis Z, Nguyen D et al. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragmentbased drug design (vFBDD). Bioorg. Med. Chem. Lett. 21(23), 7155-7165 (2011).
149. Bukhtiyarova M, Karpusas M, Northrop K, Namboodiri HVM, Springman EB. Mutagenesis of p38a MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state. Biochemistry 46, 5687-5696 (2007).
150. Kluter S, Grutter C, Naqvi T et al. Displacement assay for the detection of stabilizers of inactive kinase conformations. J. Med. Chem. 53(1), 357-367 (2010).
151. Ahn YM, Clare M, Ensinger CL et al. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorg. Med. Chem. Lett. 20(19), 5793-5798 (2010).
152. Over B, Wetzel S, Grutter C et al. Naturalproduct- derived fragments for fragment-based ligand discovery. Nat. Chem. 5(1), 21-28 (2013).
153. Tecle H, Feru F, Liu H et al. The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay. Chem. Biol. Drug Design 74(6), 547-559 (2009).
154. Tzarum N, Eisenberg-Domovich Y, Gills JJ, Dennis PA, Livnah O. Lipid molecules induce p38alpha activation via a novel molecular switch. J. Mol. Biol. 424(5), 339-353 (2012).
155. Warmus JS, Flamme C, Zhang LY et al. 2-alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase). Bioorg. Med. Chem. Lett. 18(23), 6171-6174 (2008).
156. Fischmann TO, Smith CK, Mayhood TW et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 48(12), 2661-2674 (2009).
157. Iverson C, Larson G, Lai C et al. RDEA119/ BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 69(17), 6839-6847 (2009).
158. Wallace MB, Adams ME, Kanouni T et al. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors. Bioorg. Med. Chem. Lett. 20(14), 4156-4158 (2010).
159. Isshiki Y, Kohchi Y, Iikura H et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg. Med. Chem. Lett. 21(6), 1795-1801 (2011).
160. Dong Q, Dougan DR, Gong X et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg. Med. Chem. Lett. 21(5), 1315-1319 (2011).
161. Rice KD, Aay N, Anand NK et al. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med. Chem. Lett. 3, 416-421 (2012).
162. Meier C, Brookings DC, Ceska TA et al. Engineering human MEK-1 for structural studies: a case study of combinatorial domain hunting. J. Struct. Biol. 177(2), 329-334 (2012).
163. Heald RA, Jackson P, Savy P et al. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions. J. Med. Chem. 55, 4594-4604 (2012).
164. Hartung IV, Hitchcock M, Puhler F et al. Optimization of allosteric MEK inhibitors. Part 1: venturing into underexplored SAR territories. Bioorg. Med. Chem. Lett. 23(8), 2384-2390 (2013).
165. Sadowsky JD, Burlingame MA, Wolan DW, McClendon CL, Jacobson MP, Wells JA. Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl Acad. Sci. USA 108(15), 6056-6061 (2011).
166. Gilsbach BK, Ho FY, Vetter IR, Van Haastert PJ, Wittinghofer A, Kortholt A. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc. Natl Acad. Sci. USA 109(26), 10322-10327 (2012).
167. Fujino A, Fukushima K, Namiki N, Kosugi T, Takimoto-Kamimura M. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800. Acta Crystallogr. D Biol. Crystallogr. 66(Pt 1), 80-87 (2010).
168. Chan WW, Wise SC, Kaufman MD et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switchcontrol inhibitor DCC-2036. Cancer Cell 19(4), 556-568 (2011).
169. Salah E, Ugochukwu E, Barr AJ, Von DF, Knapp S, Elkins JM. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J. Med. Chem. 54 , 2359-2367 (2011).
170. Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GP, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS ONE 5(9), e12913 (2010).
171. Schneider EV, Boettcher J, Huber R, Maskos K, Neumann L. Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc. Natl Acad. Sci. USA 110, 8081-8086 (2013).
172. Bhattacharya SK, Aspnes GE, Bagley SW et al. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors. Bioorg. Med. Chem. Lett. 22(24), 7523-7529 (2012).
173. Xie T, Peng W, Liu Y et al. Structural basis of RIP1 inhibition by necrostatins. Structure 21(3), 493-499 (2013).
174. Eswaran J, Knapp S. Insights into protein kinase regulation and inhibition by large scale structural comparison. Biochim. Biophys. Acta 1804(3), 429-432 (2010).